HealthcareServices

Neurogenetic Testing Market Growth Projection: Expected to Surpass $1.24 Billion by 2030 at 11.9% CAGR

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neurogenetic testing market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Neurogenetic Testing Market’s size between 2026 and 2030?_x000D_

The neurogenetic testing market size has seen rapid expansion in recent years. This market is set to increase from $0.7 billion in 2025 to $0.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.5%. The market’s past growth can be attributed to the early adoption of PCR-based genetic testing, the rising incidence of inherited neurological disorders, the increased utilization of microarray platforms, advancements in early diagnostic techniques, and the initial integration of genetic screening into clinical workflows._x000D_

_x000D_

The neurogenetic testing market is anticipated to undergo significant growth in the upcoming years, with its valuation expected to reach $1.24 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.9%. This projected expansion during the forecast period is driven by factors such as the increasing demand for next-generation sequencing, the expanding application of clinical exome sequencing, a rise in investment dedicated to genetic research, the development of sophisticated molecular diagnostic tools, and the growing adoption of personalized neurological treatment approaches. Key trends for this period include the increased uptake of whole-exome sequencing technologies, a greater reliance on PCR-based neurological genetic tests, the broader implementation of microarray analysis, an expansion in testing capabilities for rare neurological genetic disorders, and a growing emphasis on early diagnosis and predictive testing._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp_x000D_

_x000D_

Which Drivers Are Shaping Strategic Decisions In The Neurogenetic Testing Market?_x000D_

An increase in the occurrence of neurological conditions is anticipated to fuel the expansion of the neurogenetic testing market. These conditions encompass any ailments impacting the nervous system, specifically the brain, spinal cord, and nerves. Their increasing occurrence can be attributed to factors such as genetic predisposition, infections, physical trauma, exposure to toxins, autoimmune reactions, and degenerative processes. Neurogenetic testing substantially improves the diagnosis, therapeutic approaches, and overall management of neurological disorders. It achieves this by providing individualized understanding of genetic predispositions, aiding in treatment selection, and enabling patients and their families to make well-informed health decisions, ultimately leading to better patient care and results. As an illustration, in October 2023, the World Federation of Neurology, a UK-based charity, reported that neurological disorders, indicating a rapidly growing global health burden, are now the second-leading cause of mortality and the primary contributor to disability globally. More than 40 percent of the world’s population was affected in 2023, and the count of people suffering from brain diseases is expected to nearly double by 2050. Consequently, the growing frequency of neurological disorders is set to stimulate the expansion of the neurogenetic testing market._x000D_

_x000D_

What Segment Classifications Make Up The Neurogenetic Testing Market?_x000D_

The neurogenetic testing market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types_x000D_

2) By Disease: Rare Genetic Disorder, Huntington’s Disease, Fragile X Syndrome, Other Diseases_x000D_

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories_x000D_

_x000D_

Subsegments:_x000D_

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray_x000D_

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing_x000D_

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection_x000D_

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)_x000D_

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing_x000D_

_x000D_

What Trends Are Expected To Impact The Competitive Landscape Of The Neurogenetic Testing Market?_x000D_

Major companies within the neurogenetic testing market are actively developing innovative solutions, such as whole-genome sequencing, to improve the precision and extent of genetic analysis, thereby providing more thorough and individualized testing for neurological conditions. Whole-genome sequencing (WGS) represents a comprehensive genetic testing approach that involves mapping an individual’s entire DNA sequence. For example, in March 2024, Nucleus Genomics, a US-based company specializing in genetic analysis, introduced a new DNA analysis product. This platform is designed to furnish individuals with a deeper insight into their genetic predispositions, enabling them to make knowledgeable choices concerning their health and overall welfare. By combining state-of-the-art technology with expert genetic counseling services, Nucleus Genomics intends to reshape the field of genetic testing, making whole-genome sequencing directly available to people and revolutionizing genomic medicine._x000D_

_x000D_

Which Major Industry Participants Are Leading The Neurogenetic Testing Market Growth?_x000D_

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services_x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report_x000D_

_x000D_

Which Geographic Areas Are Emerging As Strong Markets For The Neurogenetic Testing Market?_x000D_

North America was the largest region in the neurogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Neurogenetic Testing Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Neurogenetic Testing Market 2026, By The Business Research Company#_x000D_

_x000D_

Dna Testing Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/dna-testing-global-market-report_x000D_

_x000D_

Genetic Testing Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report_x000D_

_x000D_